ARCHIVES

Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

DCT Board Okays New Surgery RFA, Will Hear Request For Support Of 30 Surgical Centers

April 11, 1980

Revlimid Also Demonstrates Response in Mantle Cell

July 29, 2011

NCI Bypass Budget Calls For $5.98 Billion

December 6, 2002

NCI Adds $700,000 to CCOP Budget, Makes Four New Awards

June 9, 1989

Radiation To Stem Cell Niche Improved PFS In Glioblastoma

August 27, 2010

In Brief: CTEP Files IND For Antineoplaston, Mayo, MSK, Plan Trials; Researcher Escapes Bosnia

August 6, 1993